Pharmaceuticals Thailand

Thailand MASH (NASH) Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Thailand MASH (NASH) Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Thailand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.0 Mn Placeholder estimate
Estimate 2025 $2.8 Mn 0.1% of the global market
Projected 2034 $69.4 Mn 2,338.2% Adds $66.6 Mn over 9 forecast years
CAGR 2025–2034 42.6% Faster than 99% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Thailand is 0.12% of the global market.
  • In APAC, the largest is China at $193.6 Mn.
  • Fastest growing: India at 44.6% a year.
  • Thailand ranks 10th of 10 by size in APAC.

Market size projection

Thailand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$66.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
MASH (NASH) Therapeutics Market market size by year, Thailand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.0 Mn — —
2025 (base) $2.8 Mn +$0.9 Mn —
2026 (forecast) $4.1 Mn +$1.2 Mn +42.6%
2027 (forecast) $5.8 Mn +$1.7 Mn +103.3%
2028 (forecast) $8.3 Mn +$2.5 Mn +190%
2029 (forecast) $11.8 Mn +$3.5 Mn +313.5%
2030 (forecast) $16.8 Mn +$5.0 Mn +489.7%
2031 (forecast) $23.9 Mn +$7.2 Mn +740.8%
2032 (forecast) $34.1 Mn +$10.2 Mn +1,099%
2033 (forecast) $48.7 Mn +$14.5 Mn +1,609.8%
2034 (forecast) $69.4 Mn +$20.7 Mn +2,338.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Thailand MASH (NASH) Therapeutics Market Analysis at a glance
Market size, 2025$2.8 Mn placeholder estimate
Forecast, 2034$69.4 Mn placeholder estimate
Growth (CAGR), 2025–203442.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledMASH Drugs
SegmentsDrug class, stage and end user (see all)
Key playersMadrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and 1 more (see all)
Regulator in ThailandThai FDASource: Thai Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Thailand MASH (NASH) Therapeutics Market Analysis Executive Summary

MASH therapeutics treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease that can lead to cirrhosis and liver failure.

Key segments of the MASH (NASH) Therapeutics market include drug class (THR-beta Agonists, GLP-1 Agonists and FGF21 Analogs) and stage (Fibrosis Stage F2-F3 and Compensated Cirrhosis).

Bar chart: Thailand MASH (NASH) Therapeutics market size, 2024–2034, placeholder estimates. $2.0 Mn in 2024, $2.8 Mn in 2025 and $69.4 Mn in 2034, 42.6% CAGR.
Thailand MASH (NASH) Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Thailand MASH (NASH) Therapeutics Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the MASH (NASH) Therapeutics market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the MASH (NASH) Therapeutics market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for MASH (NASH) Therapeutics Market in Thailand

The MASH (NASH) Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for MASH (NASH) Therapeutics Market in Thailand

MASH (NASH) Therapeutics in Thailand: rules and payment

Medicines need registration with the Thai Food and Drug Administration (Thai FDA).⁠[1] The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes.⁠[2]

[1] Thai Food and Drug Administration. Checked 14 Nov 2026.

[2] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for MASH (NASH) Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Thailand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in MASH (NASH) Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

MASH (NASH) Therapeutics in context

Thailand compared

  • Health spending per person: 327 US$ per person (2023). World: 1,317 US$ per person (2023). 7th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.54 per 1,000 people (2021). World: 1.86 per 1,000 people (2022). 13th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 16.0% of people (2025). World: 10.4% of people (2025). 5th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the MASH (NASH) Therapeutics market in Thailand?
Placeholder estimate: about $2.8 Mn in 2025, rising to about $69.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the MASH (NASH) Therapeutics market in Thailand growing?
Placeholder estimate: about 42.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the MASH (NASH) Therapeutics market report cover?
The report splits the market by drug class (THR-beta Agonists, GLP-1 Agonists, FGF21 Analogs, PPAR Agonists), stage (Fibrosis Stage F2-F3, Compensated Cirrhosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the MASH (NASH) Therapeutics market?
Key players include Madrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and Boston Pharmaceuticals.
What is driving the MASH (NASH) Therapeutics market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market.
Who regulates MASH (NASH) Therapeutics in Thailand?
Medicines need registration with the Thai Food and Drug Administration (Thai FDA). Source: Thai Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in Thailand?
The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes. Source: National Health Security Office. Checked 14 Nov 2026.
How much research is published on MASH (NASH) Therapeutics?
PubMed lists 16 papers on MASH (NASH) Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Thailand

See all

Related on liver health and obesity

See the topic